Fulcrum ends sickle cell drug pociredir on FDA feedback, starts alternatives review including potential M&A

 

• Piper Sandler double downgraded Fulcrum to Underweight from Overweight, cutting its price target to $3 from $23.
• Piper Sandler's rating and target cuts followed Fulcrum's discontinuation of sickle cell drug pociredir development program.
• Multiple other brokers also lowered their ratings on Fulcrum shares today after the pociredir discontinuation announcement.

https://finviz.com/stock?t=FULC&p=d